Vandervoort Jo, Ludwig Annick
Laboratory of Pharmaceutical Technology and Biopharmacy, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium.
Nanomedicine (Lond). 2007 Feb;2(1):11-21. doi: 10.2217/17435889.2.1.11.
Nanocarriers, such as nanoparticles, liposomes and dendrimers, are used to enhance ocular drug delivery. Easily administered as eye drops, these systems provide a prolonged residence time at the ocular surface after instillation, thus avoiding the clearance mechanisms of the eye. In combination with a controlled drug delivery, it should be possible to develop ocular formulations that provide therapeutic concentrations for a long period of time at the site of action, thereby reducing the dose administered as well as the instillation frequency. In intraocular drug delivery, the same systems can be used to protect and release the drug in a controlled way, reducing the number of injections required. Another potential advantage is the targeting of the drug to the site of action, leading to a decrease in the dose required and a decrease in side effects.
纳米载体,如纳米颗粒、脂质体和树枝状大分子,被用于增强眼部药物递送。这些系统易于制成眼药水给药,滴入后在眼表具有较长的停留时间,从而避免了眼部的清除机制。结合控释给药,应该能够开发出眼部制剂,在作用部位长时间提供治疗浓度,从而减少给药剂量以及滴注频率。在眼内药物递送中,同样的系统可用于以可控方式保护和释放药物,减少所需的注射次数。另一个潜在优势是药物能够靶向作用部位,从而降低所需剂量并减少副作用。